
Options for Alcohol-Associated Liver Disease Therapies Should Include Metabolic Risk
A new appreciation for the impact of metabolic risk factors in ALD may open avenues for new treatments.
A new appreciation for the impact of metabolic risk factors in ALD may open avenues for new treatments.
The proposal focuses on establishing point-of-care testing, increasing medication access among underserved populations, and engaging community organizations to drive awareness and increase screening.
A retrospective cohort study shows that GLP-1 agonists reduced the risk of cirrhosis and HCC in patients with MASLD and Type 2 diabetes.
New AASLD guidelines broadly recommend simple, cost-effective blood-based tests and elastography for many patients with chronic liver disease.
Your DDW 2024 registration includes unlimited access to session recordings until May 16, 2025.
DDW 2024 is certified for 647.5 AMA PRA Category 1 Credit(s)™. The CME Claim Site will be open through Oct. 31.
Simple blood-based tests can be used to identify which patients with MASLD should receive liver-directed therapy, but hepatologists may need more accurate measures, says Dr. Veeral Ajmera.
Once you register, start planning your itinerary.
This year’s Diversity Symposium will cover topics including LGBTQIA+ patient health needs, post-race conscious admissions and advocacy strategies.
Explore the latest research through hundreds of sessions and thousands of posters at DDW 2024.